BLAST: Blinatumomab for minimal residual disease in patients with ALL

Frontline therapy of ALL

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL

Treatment of Ph-negative ALL in adolescents and young adults

The new era of ALL treatment

Safety considerations for inotuzumab in patients with relapsed/refractory ALL

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer

Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer

Identifying cancer susceptibility genes in paediatric ALL

Defining high-risk acute lymphoblastic leukaemia

Latest concepts in frontline therapy for paediatric ALL

Improving safety for healthcare workers and patients